Skip to content

Electra_Logo

About Us
- Leadership
- Board of Directors
Science
- SIRP
- Publications
Pipeline
- Ipsoprubart
- ELA822
Patients
- Clinical Trials
Investors
Careers

About Us
- Leadership
- Board of Directors
Science
- SIRP
- Publications
Pipeline
- Ipsoprubart
- ELA822
Patients
- Clinical Trials
Investors
Careers

—Eileen Rose, Associate Director, Research

Homepage
About Us
Science
Pipeline
Patients
Careers

Investors
Contact Us
Expanded Access Policy
Privacy Policy
Terms of Use

230 E Grand Avenue, Suite S-100
South San Francisco, CA 94080
info@electra-therapeutics.com

© Electra Therapeutics Inc.

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells

Financing enables lead product candidate, ELA026, to reach clinical proof of concept in the inflammatory disease sHLH, expansion of ELA026 into other indications, and advancement of two additional programs towards the clinic

Zip Code:

No Contact Available

Site has not yet provided contact information. You may wish to check back again in the future.

Please complete the challenge

There is no contact information available for this site at this time. Please check back later.